Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Cancer Patients Receiving PD-1/PD-L1 Blockade Therapies

Conclusions The PD-L1 level on CTCs may serve as a clinically actionable biomarker for immunotherapy, and its dynamic changes could predict the therapeutic response.IMPLICATIONS FOR PRACTICE: This study was designed to investigate the role of PD-L1 expression on circulating tumor cells in predicting and monitoring response to PD-1/PD-L1 blockade immunotherapies in patients with advanced cancer. The results of the study showed that PD-L1-high expression CTCs were both a predictive biomarker and a prognostic factor in patients with advanced cancer treated with anti-PD-1/PD-L1 mAbs. These observations suggest that PD-L1 level on CTCs is a potential clinical biomarker for immunotherapy.PMID:34516729 | DOI:10.1002/onco.13981
Source: The Oncologist - Category: Cancer & Oncology Authors: Source Type: research